TNFRSF9 and ovarian carcinoma: To explore the efficacy of anti-PD-1/CD137 mAbs plus cisplatin in the ID8 ovarian cancer model, we first treated tumor-bearing mice with i.p. injection of a dose of cisplatin followed by 2 doses of anti-PD-1/CD137 mAbs at 4 days interval.